Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma

A man in his early 50s presented with small bowel obstruction, requiring emergency laparoscopic small bowel resection for the metastatic melanoma of the jejunum with no identifiable primary lesion. One week after his first treatment with ipilimumab and nivolumab, he presented with diffuse abdominal...

Full description

Bibliographic Details
Main Authors: W. J. Mullally, F. J. Cooke, I. M. Crosbie, S. Kumar, V. E. Abernethy, E. J. Jordan, M. O’Connor, A. M. Horgan, R. Landers, J. Naidoo, P. M. Calvert
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Immunology
Subjects:
combination checkpoint inhibitors
ipilimumab
nivolumab
hematological adverse events
thrombotic-thrombocytopenic purpura
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.871217/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.871217/full

Similar Items